IL6 and metabolic syndrome: Epidemiological studies have demonstrated an increase in plasma levels of inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) in patients with metabolic syndrome (MetS) and also in those with clinically overt Type 2 DM [8].